Recurrent respiratory papillomatosis: A 2020 perspective

Benedict, Jacob J.; Derkay, Craig S.

doi:10.1002/lio2.545

Cited by 57 publications

(54 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Procedures are uncomfortable, costly, and inconvenient for patients, and can injure and scar vocal fold tissues, which further impairs voice production [ 11 ]. Although emerging adjuvant medical treatments increase intersurgical intervals in some patients, surgery remains the standard of care [ 13 , 14 , 15 , 16 ]. Prophylactic vaccination with Gardasil 9 or Gardasil is protective against HPV 6 and 11, and juvenile-onset RRP incidence has significantly decreased in countries where vaccination rates are high [ 17 , 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

A Novel In Vivo Model of Laryngeal Papillomavirus-Associated Disease Using Mus musculus Papillomavirus

King

Bilger

Rademacher

et al. 2022

Viruses

View full text Add to dashboard Cite

Recurrent respiratory papillomatosis (RRP), caused by laryngeal infection with low-risk human papillomaviruses, has devastating effects on vocal communication and quality of life. Factors in RRP onset, other than viral presence in the airway, are poorly understood. RRP research has been stalled by limited preclinical models. The only known papillomavirus able to infect laboratory mice, Mus musculus papillomavirus (MmuPV1), induces disease in a variety of tissues. We hypothesized that MmuPV1 could infect the larynx as a foundation for a preclinical model of RRP. We further hypothesized that epithelial injury would enhance the ability of MmuPV1 to cause laryngeal disease, because injury is a potential factor in RRP and promotes MmuPV1 infection in other tissues. In this report, we infected larynges of NOD scid gamma mice with MmuPV1 with and without vocal fold abrasion and measured infection and disease pathogenesis over 12 weeks. Laryngeal disease incidence and severity increased earlier in mice that underwent injury in addition to infection. However, laryngeal disease emerged in all infected mice by week 12, with or without injury. Secondary laryngeal infections and disease arose in nude mice after MmuPV1 skin infections, confirming that experimentally induced injury is dispensable for laryngeal MmuPV1 infection and disease in immunocompromised mice. Unlike RRP, lesions were relatively flat dysplasias and they could progress to cancer. Similar to RRP, MmuPV1 transcript was detected in all laryngeal disease and in clinically normal larynges. MmuPV1 capsid protein was largely absent from the larynx, but productive infection arose in a case of squamous metaplasia at the level of the cricoid cartilage. Similar to RRP, disease spread beyond the larynx to the trachea and bronchi. This first report of laryngeal MmuPV1 infection provides a foundation for a preclinical model of RRP.

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel In Vivo Model of Laryngeal Papillomavirus-Associated Disease Using Mus musculus Papillomavirus

King

Bilger

Rademacher

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Hence, HPV vaccination has led to a dramatic decline in anogenital warts and other disease incidences in populations that have achieved high vaccination rates [ 86 , 90 ]. Similar, with the increasing utilization of the 9-valent and quadrivalent HPV vaccine in Australia, Benedict and Derkay [ 91 ] have seen a significant decrease in the incidence of recurrent respiratory papillomatosis. Preliminary data from the US show a similar trend of decreased incidence after implementation of vaccination.…”

Section: Vaccinationmentioning

confidence: 71%

Relevance of Human Papillomaviruses in Head and Neck Cancer—What Remains in 2021 from a Clinician’s Point of View?

Hoffmann

Quabius

2021

Viruses

View full text Add to dashboard Cite

Human papillomaviruses (HPV) cause a subset of head and neck cancers (HNSCC). HPV16 predominantly signs responsible for approximately 10% of all HNSCC and over 50% of tonsillar [T]SCCs. Prevalence rates depend on several factors, such as the geographical region where patients live, possibly due to different social and sexual habits. Smoking plays an important role, with non-smoking patients being mostly HPV-positive and smokers being mostly HPV-negative. This is of unparalleled clinical relevance, as the outcome of (non-smoking) HPV-positive patients is significantly better, albeit with standard and not with de-escalated therapies. The results of the first prospective de-escalation studies have dampened hopes that similar superior survival can be achieved with de-escalated therapy. In this context, it is important to note that the inclusion of p16INK4A (a surrogate marker for HPV-positivity) in the 8th TMN-classification has only prognostic, not therapeutic, intent. To avoid misclassification, highest precision in determining HPV-status is of utmost importance. Whenever possible, PCR-based methods, still referred to as the "gold standard”, should be used. New diagnostic antibodies represent some hope, e.g., to detect primaries and recurrences early. Prophylactic HPV vaccination should lead to a decline in HPV-driven HNSCC as well. This review discusses the above aspects in detail.

show abstract

“…Papilloma is a rare, benign tumor with an incidence rate of 1.8 per 10,000 people [ 1 , 2 ]. It is categorized based on the site of origin as laryngeal papilloma, tracheal papilloma, bronchial papilloma, or pulmonary papillomatosis, collectively referred to as recurrent respiratory papillomatosis (RRP) [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%